Centro Nazionale di Epidemiologia, Sorveglianza e Promozione della Salute (CNESPS), Istituto Superiore di Sanita' (ISS), Rome, Italy.
Adv Drug Deliv Rev. 2012 Jan;64(1):53-68. doi: 10.1016/j.addr.2011.09.007. Epub 2011 Sep 29.
Solid tumors are characterized by an abnormal architecture and composition that limit the uptake and distribution of antitumor drugs. Over the last two decades, drugs have been identified that improve the tumor uptake and distribution of drugs that have direct antitumor effects. We propose to refer to these drugs as promoter drugs, and as effector drugs to drugs that have direct antitumor effects. Some promoter drugs have received regulatory approval, while others are in active clinical development. This review gives an overview of promoter drugs, by classifying them according to their mechanism of action: promoter drugs that modulate tumor blood flow, modify the barrier function of tumor vessels, induce tumor cell killing, and overcome stromal barriers. Eventually, we discuss those that we feel are the main conclusions to be drawn from promoter drug research that has been performed so far, and suggest areas of future investigation to improve the efficacy of promoter drugs in cancer therapy.
实体瘤的结构和组成异常，限制了抗肿瘤药物的摄取和分布。在过去的二十年中，已经发现了一些药物可以提高具有直接抗肿瘤作用的药物在肿瘤中的摄取和分布。我们建议将这些药物称为促进剂药物，并将具有直接抗肿瘤作用的药物称为效应剂药物。一些促进剂药物已获得监管部门的批准，而其他药物则正在积极进行临床开发。本文通过根据其作用机制对促进剂药物进行分类，对促进剂药物进行了概述：调节肿瘤血流的促进剂药物、改变肿瘤血管屏障功能的药物、诱导肿瘤细胞杀伤的药物和克服基质屏障的药物。最后，我们讨论了我们认为从迄今为止进行的促进剂药物研究中得出的主要结论，并提出了未来研究领域，以提高促进剂药物在癌症治疗中的疗效。
